COVID-19 Vaccine Booster Hesitancy (VBH) among Healthcare Professionals of Pakistan, a Nationwide Survey

Muhammad Subhan Arshad 1,2, Imran Masood 3, Imran Imran 4, Hamid Saeed 5, Imran Ahmad 2, Iqra Ishaq 2, Hafsa Yaseen 2, Muqarrab Akbar 6, Muhammad Omer Chaudhry 7 and Muhammad Fawad Rasool 1,*

1 Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan 60800, Pakistan
2 Department of Pharmacy, Southern Punjab Institute of Health Sciences, Multan 60000, Pakistan
3 Department of Pharmacy, The Islamia University of Bahawalpur, Bahawalpur 63100, Pakistan
4 Department of Pharmacology, Faculty of Pharmacy, Bahauddin Zakariya University, Multan 60800, Pakistan
5 University College of Pharmacy, Allama Iqbal Campus, University of the Punjab, Lahore 54000, Pakistan
6 Department of Political Science, Bahauddin Zakariya University, Multan 60800, Pakistan
7 School of Economics, Bahauddin Zakariya University, Multan 60800, Pakistan
* Correspondence: fawadrasool@bzu.edu.pk

Abstract: Background: The waning vaccine immunity and emergence of new variants of SARS-CoV-2 led health authorities across the globe to administer booster doses (BDs) of the COVID-19 vaccine. Hence, the current study aimed to assess the COVID-19 vaccine booster hesitancy (VBH) amongst Pakistani healthcare professionals (HCPs). Methods: A nationwide survey-based study was carried out from April 2022 to May 2022. The online self-administered questionnaire was utilized to collect data regarding demographics (age, gender, marital status, profession, residential area, and province), COVID-19 infection history (infection history, onset, and clinical severity of disease), previous COVID-19 vaccination (type of vaccination and the number of doses), attitudes towards BDs (acceptance, rejection, and hesitancy), and psychological drivers of VBH (perceived effectiveness, vaccine safety, risk/benefit ratio, and vaccine type preference). We assessed the association between the dependent variable attitudes of study participants, regarding BDs and independent variables (demographics, COVID-19 infection history, previous COVID-19 vaccination, and psychological drivers of VBH), by using the Chi-square test/Fisher exact test. Results: Among the 1164 study participants, 51.4% were male, and 80.4% were medical professionals. The half of study participants (52.1%) agreed to take the COVID-19 vaccine BD or had already taken it, while the rest of them refused (34.7%) or hesitated (24.2%) to take it. These attitudes of the participants were significantly associated (p < 0.001) with psychological divers about the COVID-19 vaccine BD. Conclusion: This study revealed that Pakistani HCPs hesitant to take the COVID-19 vaccine BD had concerns about the safety, efficacy, and risk/benefit ratio of the vaccine’s BD. To eliminate the hesitancy, regarding BD in HCPs, certain educational strategies should be implemented by health authorities to address the concerns of HCPs.

Keywords: COVID-19 vaccines; booster dose; vaccine hesitancy; vaccine acceptance; Pakistan

1. Introduction
Coronavirus disease 2019 (COVID-19) has caused significant morbidity and mortality all around the globe, since its emergence in late 2019 [1]. As of April 2022, worldwide, more than 505 million people been infected by COVID-19, and among them, 6.2 million died of it [2]. Mass vaccination against COVID-19 played a key role in protecting against the risk of infection and the severity of the disease to minimize the burden of the disease [3–5]. To cope with the emerging new variants and decline in humoral immunity over time, health authorities started to administer booster doses (BDs) of COVID-19 vaccines to enhance the protection of vaccinated people, as revealed by different studies [6–8].
Vaccine hesitancy is one of the major threats to global health, as a hurdle in herd immunity to protect people by vaccination [9]. The World Health Organization (WHO) has defined it as a delay in acceptance or refusal to be vaccinated, despite the accessibility of vaccination facilities [10]. Misinformation and conspiracy theories lead to vaccine hesitancy against the COVID-19 vaccination program, especially in the early phase [11–13]. The reported acceptance rate of the COVID-19 vaccine ranges from 23% to 97%, with the lowest rate from the Middle East [14]. The acceptance rate of the COVID-19 vaccine among the Pakistani population was 48% to 72%, reported in different studies [11,15–17].

Healthcare professionals (HCPs) are a high-risk population, due to the nature of their work, so they were prioritized to get vaccinated, preferably even for the administration of the BDs [18]. Therefore, achieving a high vaccination rate among HCPs is crucial, as the first group to be vaccinated and a most trusted source of guidance regarding health issues, so HCPs could be the source of credible local experiences as role models for the rest of the community [19]. The prevalence of COVID-19 vaccine booster hesitancy (VBH) among HCPs is comparable to the general population across different countries [20–25].

As of April 2022, among 121 million fully vaccinated individuals only 6.9 million received the COVID-19 vaccine BD [26]. Therefore, we aimed to assess the COVID-19 VBH and the attitude of the HCPs towards BDs in Pakistan. Furthermore, the secondary objective was to determine the association between independent variables (demographics, COVID-19 infection history, vaccination history, and psychological drivers) with attitude towards BD and the potential predictors of vaccine acceptance among the targeted population.

2. Materials and Methods

2.1. Study Design, Population, and Sample Size

A web-based, self-administered questionnaire (SAQ) was used to collect data under a cross-sectional study design from April 2022 to May 2022. The HCPs currently living in Pakistan and aged more than 18 years were included in the study. The strengthening the reporting of observational studies in epidemiology (STROBE) guidelines were followed to report this cross-sectional study [27]. A minimum sample size of 1068 was calculated through an online sample size calculator (Rao soft), with a 3% margin of error, 95% confidence interval, 50% response distribution, and targeted population size of 485,277, based on a report by the Pakistan Bureau of Statistics [28], which was further inflated by 10% (N = 107) to counteract any errors in the completion of SAQ, resulting in a final sample size of 1175.

2.2. Questionnaire

A pre-validated SAQ from the previous study (among the HCPs of Czechia, regarding COVID-19 VBH) was utilized to prepare the draft SAQ [20]. That SAQ comprised five sections, with a total of 19 close-ended questions. The first section comprised questions regarding demographic data of the participants, i.e., age, gender (male/female), marital status (married/single), profession (physician/dentist/pharmacist/nurse/supportive staff), residential area (rural/urban), and province (Punjab/Sindh/Baluchistan/KPK/Capital Islamabad/Gilgit Baltistan). The second section included questions about COVID-19 vaccination history (yes/no), type of vaccination, the number of doses (one/two/three), and side effects experienced after vaccination (yes/no). While the questions about COVID-19 infection history (yes/no/maybe), onset (before 1st dose/between doses/after 2nd dose), and clinical severity of disease (mild/moderate/severe/critical) were included in the third section. In the fourth section, participants were asked about their willingness to take the COVID-19 vaccine’s BD (yes/no/maybe). The fifth section comprised the possible psychological drivers of COVID-19 vaccine BD acceptance, i.e., (a) perceived effectiveness: preventing severe illness, symptomatic infection, community transmission, and mutations, (b) perceived safety: equally safe as previous doses and seriousness of side effects, (c) perceived risk/benefit ratio and prioritization to take BD, and (d) vaccine previous dose satisfaction, vaccine selectivity, and vaccine type preference.
The expert panel of subject specialists, related to pharmacy practice and public health, assured the content validity of the SAQ. To confirm the face validity and reliability of the SAQ, a pilot study was performed in the targeted population, with a sample size of 30. The SAQ was found reliable, with a Cronbach alpha’s value of 0.8.

2.3. Data Collection

A snowball technique was utilized to collect data from the targeted population (HCPs) by designing an online version of SAQ via Google Forms (Google LLC, Menlo Park, CA, USA), whose link was distributed through several platforms, such as WhatsApp, Facebook, E-mail, etc. The checklist for reporting results of internet E-surveys (CHERRIES) guidelines were followed for online survey conduction and data collection [29].

2.4. Ethics

Electronic informed consent was acquired from every participant before the administration of the study questionnaire. To avoid the Hawthorne bias, no data were collected in the study that could reveal the identity of participants, to ensure their privacy. The current study was approved by the ethics committee of the Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan (reference No. Acad/PRAC/22/03). This study was conducted under the Declaration of Helsinki.

2.5. Statistical Analysis

The statistical analyses were performed by utilizing the statistical package for the social sciences (SPSS), version 21.0 (IBM, Armonk, NY, USA). To present all the study variables, descriptive statistics were utilized, whereas categorical variables were presented as frequencies (n) and percentages (%). To test the association between independent variables (demographics, COVID-19 vaccination history, COVID-19 infection history, psychological drivers) and the dependent variable of attitude towards BD, inferential analyses were performed utilizing the Chi-square test ($\chi^2$). Fisher’s exact test was used for a test with a predicted cell count of less than 5. After that, univariate logistic regression analysis was performed to identify possible predictors of vaccine for each significant independent variable in $\chi^2$ analysis. The proposed psychological drivers were analyzed through multivariate regression analysis, after being adjusted for gender, marital status, residential area, vaccine type taken, vaccination side effects, and infection history. A significance level of $\leq 0.05$ was considered statistically significant, and a confidence level of 95% was assumed during all the inferential statistics.

3. Results

Among the total 1190 respondents, 26 responses were excluded from the final analysis, due to incompleteness, which led to a completeness rate of 97.8%. Out of 1164 study participants, 598 (51.4%) were male, and 566 (48.6%) were female, with a mean age of 28.79 (SD ± 5.01) years. Amongst the study participants, 831 (71.5%) were unmarried, and 936 (80.4%) belonged to a medical profession (physician, dentist, and pharmacist). Among them, 821 (71.0%) were from the province of Punjab, and 880 (75.6%) were living in urban areas. The demographic details of the survey participants are presented in Table 1.

Among the study participants, only 272 (23.4%) reported being infected by COVID-19 (confirmed by test). Amongst those who were infected by COVID-19, 55.9% were infected before the first dose of vaccination, and 66.9% reported mild severity of the disease. A total of 304 (26.1%) participants reported their previous infection status as “maybe” because they never tested for it. There was a statistically significant difference ($p < 0.001$) in reported COVID-19 infection history across gender, as females (30.4%) were most commonly infected, as compared to males (16.7%). The onset and severity of the disease had a significant association with the profession, gender, and age groups of the participants, details can be seen in Table 2.
### Table 1. Demographic details of the respondents (N = 1164).

| Variables     | Outcomes  | Frequency | Percentage |
|---------------|-----------|-----------|------------|
| Age Groups    | <30 Years | 772       | 66.3%      |
|               | ≥30 Years | 392       | 33.7%      |
| Gender        | Male      | 598       | 51.4%      |
|               | Female    | 566       | 48.6%      |
| Marital Status| Single    | 832       | 71.5%      |
|               | Married   | 332       | 28.5%      |
| Profession    | Medical Professionals | 936 | 80.4% |
|               | Allied Health Professionals | 228 | 19.6% |
| Residential Area | Urban     | 880       | 75.6%      |
|                | Rural     | 284       | 24.4%      |
| Province      | Punjab    | 826       | 71.0%      |
|               | Sindh     | 143       | 12.3%      |
|               | Baluchistan | 72   | 6.2%    |
|               | Capital Islamabad | 61  | 5.2%    |
|               | AJK/Gilgit-Baltistan | 62  | 5.3%    |

The majority of the participants (95.7%) were vaccinated against COVID-19. Most of them received two doses (82.8%), and the rest received either three doses (9.9%) or one dose (7.4%). According to participants reporting, the most commonly administered vaccine is the inactivated virus vaccine (75.4%), followed by the mRNA vaccine (15.4%). Among those vaccinated participants, only 18% reported that they had experienced any side effects after vaccination. There were significant gender- ($p = 0.008$) and age-based ($p < 0.001$) differences in the type of vaccine administered (Table 3). Medical professionals (11.2%), females (11.2%), and participants aged ≥30 years (13.8%) significantly received the third dose of COVID-19 vaccine, as compared to allied health professionals (4.6%), male (8.7%), and aged less than 30 (8.0%).

Out of 1164 study participants, 52.1% reported their acceptance (willing to take BD/already taken it) to take the COVID-19 vaccine BD, while 34.7% rejected it, and 24.2% hesitated to take it. The participant attitudes towards the COVID-19 booster had significant difference across the demographic variables, i.e., gender ($p < 0.001$), marital status ($p = 0.045$), and residential area ($p < 0.001$). The COVID-19 disease-related history (being infected ($p < 0.001$), onset ($p < 0.001$), and severity of illness ($p < 0.001$)) of the study participants was also significantly associated with the vaccination attitudes of the study participants. The vaccine acceptance (66.2%) was highest among the previously infected persons. None of the respondents with critically and severely ill conditions during the previous infection hesitated to take a BD of COVID-19 vaccine. The attitude regarding the BD of the COVID-19 vaccine had significant differences among the determinants of vaccination history (vaccine taken ($p < 0.001$), type of vaccine ($p < 0.001$), number of doses ($p < 0.001$), and experience of side effects ($p < 0.001$)) of the study participants. More than half of the participants (53.8%) who did not experience any side effects during previous doses of the vaccine accepted taking a BD. The BD acceptance was also highest among the participants who have taken the inactivated virus vaccines (80.9%), followed by the mRNA vaccines (15.6%), further details can be seen in the Table 4.
### Table 2. COVID-19-related history of the respondents.

| Variable                          | Outcomes                              | Overall (N = 1164) | Medical Professionals (N = 936) | Allied Health Professionals (N = 228) | Sig. | Male (N = 598) | Female (N = 566) | Sig. | <30 Years (N = 772) | ≥30 Years (N = 392) | Sig. |
|-----------------------------------|---------------------------------------|--------------------|---------------------------------|---------------------------------------|------|----------------|------------------|------|---------------------|---------------------|------|
| **Infected by SARS-CoV-2 (COVID-19)** | Yes †                                 | 272 (23.4%)        | 218 (23.3%)                     | 54 (23.7%)                           | 0.001| 100 (16.7%)   | 172 (30.4%)      | <0.001| 172 (22.3%)          | 100 (25.5%)          | 0.17 |
|                                   | No                                    | 588 (50.5%)        | 494 (52.8%)                     | 94 (41.2%)                           |      | 304 (50.8%)   | 284 (50.2%)      |      | 386 (50.0%)          | 202 (51.5%)          |      |
|                                   | Maybe                                 | 304 (26.1%)        | 224 (23.9%)                     | 80 (35.1%)                           |      | 194 (32.4%)   | 110 (19.4%)      |      | 214 (27.7%)          | 90 (23.0%)           |      |
| **Onset of infection †**          | Before 1st dose                       | 152 (55.9%)        | 130 (59.6%)                     | 22 (40.7%)                           | 0.004*| 40 (40%)     | 112 (65.1%)      | <0.001*| 82 (47.7%)          | 70 (70.0%)           |      |
|                                   | Between doses                         | 10 (03.7%)         | 10 (04.6%)                      | 0 (00.0%)                            |      | 0 (0.0%)      | 10 (5.8%)        |      | 10 (5.8%)            | 0 (0.0%)             |      |
|                                   | After 2nd dose                        | 110 (40.4%)        | 78 (35.8%)                      | 32 (59.3%)                           |      | 60 (60.0%)    | 50 (29.1%)       |      | 80 (46.5%)           | 30 (30.0%)           |      |
| **Severity of infection †**       | Mild                                  | 182 (66.9%)        | 140 (64.2%)                     | 42 (77.8%)                           | 0.002*| 60 (60.0%)   | 112 (65.1%)      | <0.001*| 112 (65.1%)         | 70 (70.0%)           |      |
|                                   | Moderate                               | 50 (18.4%)         | 48 (22.0%)                      | 2 (03.7%)                            |      | 70 (70.0%)    | 40 (23.3%)       |      | 50 (29.1%)           | 0 (0.0%)             |      |
|                                   | Severe                                | 30 (11.0%)         | 20 (09.2%)                      | 10 (18.5%)                           |      | 10 (10.0%)    | 20 (11.6%)       |      | 10 (5.8%)            | 20 (20.0%)           | <0.001*|
|                                   | Critical                              | 10 (03.7%)         | 10 (04.6%)                      | 0 (00.0%)                            |      | (10.0%)       | 0 (0.0%)        |      | 0 (0.0%)             | 10 (10.0%)           |      |

Bold fonts indicate the statistically significant results ($p \leq 0.05$), † Participants previously infected by COVID-19, * Fisher exact test used.

### Table 3. COVID-19 vaccine-related details of the respondents.

| Variable                              | Outcomes                               | Overall (N = 1164) | Medical Professionals (N = 936) | Allied Health Professionals (N = 228) | Sig. | Male (N = 598) | Female (N = 566) | Sig. | <30 Years (N = 772) | ≥30 Years (N = 392) | Sig. |
|---------------------------------------|----------------------------------------|--------------------|---------------------------------|---------------------------------------|------|----------------|------------------|------|---------------------|---------------------|------|
| **COVID-19 vaccine received**         | Yes †                                  | 1114 (95.7%)      | 896 (95.7%)                     | 218 (95.6%)                           | 0.940| 578 (96.7%)   | 536 (94.7%)      | 0.1  | 752 (97.4%)          | 362 (92.3%)          | <0.001|
|                                      | No                                     | 50 (4.3%)          | 40 (4.3%)                       | 10 (4.4%)                            |      | 20 (3.3%)     | 30 (5.3%)       |      | 20 (02.6%)           | 30 (07.7%)           |      |
| **Vaccine type taken †**              | mRNA vaccines                          | 172 (15.4%)       | 142 (15.8%)                     | 30 (13.8%)                           | 0.679| 82 (14.2%)    | 90 (16.8%)      | 0.008| 62 (8.2%)            | 40 (11.0%)           | <0.001|
|                                      | Adenovirus vector vaccines             | 102 (9.2%)        | 80 (8.9%)                       | 22 (10.1%)                           |      | 40 (06.9%)    | 62 (11.6%)      |      | 60 (10.6%)           | 92 (254%)            |      |
|                                      | Inactivated virus vaccines             | 840 (75.4%)       | 674 (75.2%)                     | 166 (76.1%)                          |      | 456 (78.9%)   | 384 (71.6%)     |      | 610 (81.1%)          | 230 (63.5%)           |      |
| **Doses taken †**                    | Single dose                            | 82 (7.4%)         | 72 (8.0%)                       | 10 (4.6%)                            | 0.002| 62 (10.7%)    | 20 (3.7%)       | <0.001| 50 (06.6%)           | 32 (8.8%)            | 0.003|
|                                      | Two doses                              | 922 (82.8%)       | 724 (80.8%)                     | 198 (90.8%)                          |      | 466 (80.6%)   | 456 (85.1%)     |      | 642 (85.4%)          | 280 (77.3%)           |      |
|                                      | Three doses                            | 110 (9.9%)        | 100 (11.2%)                     | 10 (4.6%)                            |      | 50 (8.7%)     | 60 (11.2%)      |      | 60 (08.0%)           | 50 (13.8%)           |      |
| ** Experienced side effects after vaccination †** | Yes                                   | 200 (18.0%)      | 128 (14.3%)                     | 72 (33.0%)                           | <0.001*| 80 (13.8%)   | 120 (22.4%)     | <0.001*| 150 (19.9%)          | 50 (13.8%)           | 0.003|
|                                      | No                                     | 904 (81.1%)       | 768 (85.7%)                     | 136 (62.4%)                          |      | 488 (84.4%)   | 416 (77.6%)     |      | 592 (78.7%)          | 312 (86.2%)           |      |
|                                      | Maybe                                  | 10 (0.9%)         | 0 (0.0%)                        | 10 (4.6%)                            |      | 10 (1.7%)     | 0 (0.0%)        |      | 10 (1.3%)            | 0 (0.0%)             |      |

Bold fonts indicate the statistically significant results ($p \leq 0.05$), † Participants vaccinated against COVID-19, * Fisher exact test used.
Table 4. The association of demographics, COVID-19 disease, and vaccination history towards attitudes of participants, regarding booster dose of COVID-19 vaccine.

| Variable | Outcomes | Acceptance N = 606 | Rejection N = 276 | Hesitancy N = 282 | Sig. |
|----------|----------|---------------------|-------------------|-------------------|------|
|          |          | N % | N % | N % |      |
| Gender   | Male     | 294 | 49.2% | 174 | 29.1% | 130 | 21.7% | <0.001 |
|          | Female   | 312 | 55.1% | 102 | 18.0% | 152 | 26.9% | 0.398 |
| Age      | <30 Years | 406 | 52.6% | 174 | 22.5% | 192 | 24.9% | 0.045 |
|          | ≥30 Years | 200 | 51.0% | 102 | 26.0% | 90  | 23.0% | 0.157 |
| Marital status | Single | 414 | 49.8% | 206 | 24.8% | 212 | 25.5% | 0.045 |
|          | Married  | 192 | 57.8% | 70  | 21.1% | 70  | 21.1% | 0.045 |
| Profession | Medical professionals | 476 | 50.9% | 232 | 24.8% | 228 | 24.4% | 0.045 |
|          | Allied Health Professionals | 130 | 57.0% | 44  | 19.3% | 54  | 23.7% | 0.045 |
| Residential area | Urban | 526 | 59.8% | 152 | 17.3% | 202 | 23.0% | <0.001 |
|          | Rural    | 80  | 28.2% | 124 | 43.7% | 80  | 28.2% | 0.045 |
| COVID-19 vaccine received | Yes † | 576 | 51.7% | 256 | 23.0% | 282 | 25.3% | <0.001 |
|          | No      | 30  | 60.0% | 20  | 40.0% | 0   | 0.0% | 0.045 |
| Vaccine type taken † | mRNA vaccine | 90  | 15.6% | 52  | 20.3% | 30  | 10.6% | <0.001 |
|          | Adenovirus vector vaccines | 20  | 3.5%  | 40  | 15.6% | 42  | 14.9% | <0.001 |
|          | Inactivated virus vaccine | 466 | 80.9% | 164 | 64.1% | 210 | 74.5% | <0.001 |
| Doses taken † | Single dose | 40  | 48.8% | 22  | 26.8% | 20  | 24.4% | <0.001 |
|          | Two doses | 436 | 47.3% | 234 | 25.4% | 252 | 27.3% | <0.001 |
|          | Three doses | 100 | 90.9% | 0   | 0.0% | 10  | 9.1% | <0.001 |
| Experienced side effects after vaccination † | Yes | 90  | 45.0% | 50  | 25.0% | 60  | 30.0% | <0.001 |
|          | No      | 486 | 53.8% | 206 | 22.8% | 212 | 23.5% | <0.001 |
|          | Maybe   | 0   | 0.0%  | 0   | 0.0% | 10  | 100.0% | <0.001 |
| Infected by SARS-CoV-2 (COVID-19) | Yes ‡ | 180 | 66.2% | 42  | 15.4% | 50  | 18.4% | <0.001 |
|          | No      | 264 | 44.9% | 172 | 29.3% | 152 | 25.9% | <0.001 |
|          | Maybe   | 162 | 53.3% | 62  | 20.4% | 80  | 26.3% | <0.001 |
| Onset    | Before 1st dose | 100 | 65.8% | 32  | 21.1% | 20  | 13.2% | <0.001 |
|          | Between doses | 10  | 100.0% | 0   | 0.0% | 0   | 0.0% | <0.001 |
|          | After 2nd dose | 70  | 63.6% | 10  | 9.1% | 30  | 27.3% | <0.001 |
| Severity of infection | Mild | 110 | 60.4% | 32  | 17.6% | 40  | 22.0% | <0.001 |
|          | Moderate | 40  | 80.0% | 0   | 0.0% | 10  | 20.0% | <0.001 |
|          | Severe   | 20  | 66.7% | 10  | 33.3% | 0   | 0.0% | <0.001 |
|          | Critical | 10  | 100.0% | 0   | 0.0% | 0   | 0.0% | <0.001 |

Bold fonts indicate the statistically significant results (p ≤ 0.05). † Participants vaccinated against COVID-19, ‡ participants previously infected by COVID-19, * Fisher exact test used.
The study participants reported their views regarding various drivers related to COVID-19 vaccine BD on a three-point Likert scale (agree, neutral, and disagree). Among the study participants, 50.3%, 49.5%, and 47.8% agreed about protection against severe illness, symptomatic infection, and community transmission by administration of BD. Half of the participants (50.2%) agreed that currently available BDs are safer than previous doses, and more than half of the participants (54.6%) worried about side effects due to vaccination, as compared to previous doses. In response to the driver regarding perceived susceptibility, 53.8% of participants agreed that a BD's benefits outweighs its risk, and 52.9% agreed to receive a BD on priority bases. The majority of participants (69.7%) preferred to take the mRNA vaccines as a BD, followed by the inactivated virus vaccines (24.7%). All the psychological drivers were also significantly associated ($p < 0.001$) with the attitude of the study participants toward the BD of the COVID-19 vaccine. The higher levels of BD acceptance (72.4%, 75.7%, and 68.7%) were present among the participants having an agreement with the perceived effectiveness of BD for severe illness, symptomatic infection, and community transmission, respectively. Likewise, participants who agreed with the perceived safety of the BD have a higher level of BD acceptance (74.3%), as compared to others having disagreement (29.4%) with that statement. The detailed psychological determinants of COVID-19 vaccine BD-related attitudes of the study participants can be seen in Table 5. The BD accepting (76.6%), rejecting (55.8%), and hesitant (53.2%) groups of HCPs are stated to promote the mRNA vaccines, such as BD.

The significantly associated independent variables in the Chi-square test were included in the univariate regression analysis to assess the possible predictors of vaccine acceptance. The female Pakistani HCPs were $1.270 (1.009–1.599)$ more likely to be accepting of the COVID-19 vaccine BD, as compared to males and married Pakistani HCPs, which were $1.385 (1.071–1.790)$ times more expected to accept BD, as compared to unmarried. The participants who had previously taken the inactivated virus vaccine and mRNA vaccine were $5.109 (3.076–7.982)$ and $4.500 (2.537–7.982)$ times more likely to be willing to take the BD, as compared to those who had taken the adenovirus vector vaccine previously (Table 6).
Table 5. The association of psychological determinants of COVID-19 vaccine booster dose with vaccination attitudes of participants.

| Variables                                                                 | Outcomes                                                                 | Overall | Acceptance N = 606 | Rejection N = 276 | Hesitancy N = 282 | Sig.  |
|----------------------------------------------------------------------------|--------------------------------------------------------------------------|---------|--------------------|-------------------|-------------------|-------|
| Vaccine’s booster dose will protect against severe COVID-19 infection       | Agree                                                                    | 586     | 50.3%              | 424               | 72.4%             | 70    | 11.9% | 92    | 15.7% | <0.001 |
| (severe illness).                                                          | Neutral                                                                  | 486     | 41.8%              | 162               | 33.3%             | 144   | 29.6% | 180   | 37.0% | 10.9%  |
|                                                                            | Disagree                                                                 | 92      | 7.9%               | 20                | 21.7%             | 62    | 67.4% | 10    | 10.9% | 15.6%  |
| Vaccine’s booster dose will protect from symptoms of COVID-19 infection    | Agree                                                                    | 576     | 49.5%              | 436               | 75.7%             | 50    | 8.7%  | 90    | 15.6% | <0.001 |
| (symptomatic infection).                                                   | Neutral                                                                  | 432     | 37.1%              | 140               | 32.4%             | 130   | 30.1% | 162   | 37.5% | 10.9%  |
|                                                                            | Disagree                                                                 | 156     | 13.4%              | 30                | 19.2%             | 96    | 61.5% | 30    | 19.2% | 10.9%  |
| Booster doses of the COVID-19 vaccine will prevent transmission of         | Agree                                                                    | 556     | 47.8%              | 382               | 68.7%             | 82    | 14.7% | 92    | 16.5% | <0.001 |
| SARS-CoV-2 and its variants in the community (community transmission).     | Neutral                                                                  | 476     | 40.9%              | 174               | 36.6%             | 132   | 27.7% | 170   | 35.7% | 10.9%  |
|                                                                            | Disagree                                                                 | 132     | 11.3%              | 50                | 37.9%             | 62    | 47.0% | 20    | 15.2% | 10.9%  |
| Booster doses are similarly safe as were previous doses of COVID-19        | Agree                                                                    | 584     | 50.2%              | 434               | 74.3%             | 90    | 15.4% | 60    | 10.3% | <0.001 |
| vaccines (equal safety).                                                   | Neutral                                                                  | 478     | 41.1%              | 142               | 29.7%             | 144   | 30.1% | 192   | 40.2% | <0.001 |
|                                                                            | Disagree                                                                 | 102     | 8.8%               | 30                | 29.4%             | 42    | 41.2% | 30    | 29.4% | <0.001 |
| Administration of booster doses will produce more severe side effects,    | Agree                                                                    | 636     | 54.6%              | 486               | 76.4%             | 90    | 14.2% | 60    | 9.4%  | <0.001 |
| in comparison to the previous dose (inferior safety).                     | Neutral                                                                  | 414     | 35.6%              | 90                | 21.7%             | 134   | 32.4% | 190   | 45.9% | <0.001 |
|                                                                            | Disagree                                                                 | 114     | 9.8%               | 30                | 26.3%             | 52    | 45.6% | 32    | 28.1% | <0.001 |
| The benefits of the COVID-19 vaccine’s booster dose are greater than its  | Agree                                                                    | 626     | 53.8%              | 394               | 62.9%             | 102   | 16.3% | 130   | 20.8% | <0.001 |
| risks (risk–benefit ratio).                                               | Neutral                                                                  | 406     | 34.9%              | 172               | 42.4%             | 124   | 30.5% | 110   | 27.1% | <0.001 |
|                                                                            | Disagree                                                                 | 132     | 11.3%              | 40                | 30.3%             | 50    | 37.9% | 42    | 31.8% | <0.001 |
| I will receive the COVID-19 vaccine’s booster dose on priority bases      | Agree                                                                    | 616     | 52.9%              | 422               | 68.5%             | 94    | 15.3% | 100   | 16.2% | <0.001 |
| (self-priority).                                                          | Neutral                                                                  | 418     | 35.9%              | 164               | 39.2%             | 102   | 24.4% | 152   | 36.4% | <0.001 |
|                                                                            | Disagree                                                                 | 130     | 11.2%              | 20                | 15.4%             | 80    | 61.5% | 30    | 23.1% | <0.001 |
| I will prefer to take the COVID-19 vaccine’s booster dose after           | Agree                                                                    | 406     | 34.9%              | 142               | 35.0%             | 164   | 40.4% | 100   | 24.6% | <0.001 |
| evidence-based confirmation of its capability to prevent circulating new   | Neutral                                                                  | 426     | 36.6%              | 234               | 54.9%             | 82    | 19.2% | 110   | 25.8% | <0.001 |
| variants of SARS-CoV-2 (mutation control).                                | Disagree                                                                 | 332     | 28.5%              | 230               | 69.3%             | 30    | 9.0%  | 72    | 21.7% | <0.001 |
| I will prefer to take a different type/brand of vaccine as a booster     | Agree                                                                    | 352     | 30.2%              | 230               | 65.3%             | 52    | 14.8% | 70    | 19.9% | <0.001 |
| dose from earlier doses (vaccine satisfaction).                           | Neutral                                                                  | 568     | 48.8%              | 244               | 43.0%             | 152   | 26.8% | 172   | 30.3% | <0.001 |
|                                                                            | Disagree                                                                 | 244     | 21.0%              | 132               | 54.1%             | 72    | 29.5% | 40    | 16.4% | 10.9%  |
Table 5. Cont.

| Variables                                                                 | Outcomes                  | Overall       | Acceptance N = 606 | Rejection N = 276 | Hesitancy N = 282 | Sig.   |
|--------------------------------------------------------------------------|---------------------------|---------------|--------------------|-------------------|-------------------|--------|
|                                                                           | N | %age | N | %age | N | %age | N | %age |
| Certain COVID-19 vaccine types/brands should be purchased by the government to administer as a booster dose (vaccine selectivity). |   |      |   |      |   |      |   |      |
| Agree                                                                    | 454 | 39.0% | 282 | 62.1% | 70 | 15.4% | 102 | 22.5% | <0.001 |
| Neutral                                                                  | 496 | 42.6% | 212 | 42.7% | 134 | 27.0% | 150 | 30.2% |        |
| Disagree                                                                 | 214 | 18.4% | 112 | 52.3% | 72 | 33.6% | 30  | 14.0% |        |
| Which COVID-19 vaccine type should be promoted as a booster dose (preferred vaccine). |   |      |   |      |   |      |   |      |
| mRNA Vaccines                                                            | 768 | 69.7% | 464 | 76.6% | 154 | 55.8% | 150 | 53.2% | <0.001 |
| Adenovirus vector vaccines                                              | 62  | 5.6%  | 10  | 01.7% | 42  | 15.2% | 72  | 25.5% |        |
| Inactivated virus vaccines                                               | 272 | 24.7% | 132 | 21.8% | 80  | 29.0% | 60  | 21.3% |        |

Bold fonts indicate the statistically significant results ($p \leq 0.05$).
Table 6. Univariate regression analysis of the predictors of COVID-19 vaccine BD acceptance among study participants.

| Predictors                                           | B    | SE   | Wald  | OR (CI 95%)         | Sig.  |
|------------------------------------------------------|------|------|-------|---------------------|-------|
| Gender (female vs. male)                              | 0.239| 0.118| 4.133 | 1.270 (1.009–1.599) | 0.042 |
| Marital status (married vs. single)                   | 0.325| 0.131| 6.173 | 1.385 (1.071–1.790) | 0.013 |
| Residential area (urban vs. rural)                    | 1.332| 0.149| 80.192| 3.789 (2.831–5.072) | <0.001|
| Vaccinated (yes vs. no)                               | 0.337| 0.295| 1.308 | 0.714 (0.400–1.272) | 0.253 |
| Vaccine type taken (mRNA vaccine vs. adenovirus vector vaccines) | 1.504| 0.292| 23.459| 4.500 (2.537–7.982) | <0.001|
| Vaccine type taken (inactivated virus vaccine vs. adenovirus vector vaccines) | 1.631| 0.259| 39.691| 5.109 (3.076–7.982) | <0.001|
| Side effects after vaccination (no vs. yes)           | 0.328| 0.157| 4.368 | 1.388 (1.021–1.887) | 0.037 |
| Previously infected (yes vs. no)                      | 0.761| 0.145| 27.678| 2.140 (1.612–2.842) | <0.001|

Bold fonts indicate the statistically significant results ($p \leq 0.05$).

The proposed psychological drivers of COVID-19 vaccine BD acceptance were assessed by using multivariate logistic regression analysis, while adjusting for significant independent variables in univariate analysis. The participants who had an agreement with the ability of BD to control severe illness and symptomatic infection were 3.181 (2.004–5.050) and 2.770 (1.812–4.234) more likely to be accepting BD, as compared to their counterparts. The participants who agreed with an equal safety profile of BD as that of the primer doses and had satisfaction regarding the previous vaccine types administered to them were 4.220 (2.814–6.329) and 2.144 (1.431–3.213) more likely to be willing to obtain a BD of the COVID-19 vaccine (Table 7).

Table 7. Multivariate logistic regression analysis of proposed psychological drivers for acceptance of COVID-19 vaccine BD among the healthcare professionals of Pakistan.

| Predictors                          | B    | SE   | Wald  | OR (CI 95%)         | Sig.  |
|-------------------------------------|------|------|-------|---------------------|-------|
| Severe Illness: Agree               | 1.157| 0.236| 24.099| 3.181 (2.004–5.050) | <0.001|
| Symptomatic Infection: Agree        | 1.019| 0.217| 22.142| 2.770 (1.812–4.234) | <0.001|
| Community Transmission: Agree       | −0.259| 0.226| 1.307 | 0.772 (0.496–1.203) | 0.253 |
| Equal Safety: Agree                 | 1.440| 0.207| 48.514| 4.220 (2.814–6.329) | <0.001|
| Inferior Safety: Disagree           | −0.858| 0.322| 7.100 | 0.424 (0.225–0.797) | 0.008 |
| Risk Benefit Ratio: Agree           | −1.329| 0.275| 23.351| 0.265 (0.155–0.454) | <0.001|
| Self-Priority: Agree                | 1.062| 0.253| 17.598| 2.891 (1.761–4.748) | <0.001|
| Mutation Control: Disagree          | 0.066| 0.209| 0.100 | 1.068 (0.709–1.610) | 0.752 |
| Vaccine Satisfaction: Agree         | 0.763| 0.206| 13.672| 2.144 (1.431–3.213) | <0.001|
| Vaccine Selectivity: Agree          | −0.482| 0.201| 5.752 | 0.617 (0.416–0.916) | 0.016 |

Bold fonts indicate the statistically significant results ($p \leq 0.05$).

4. Discussion

The BD of the COVID-19 vaccine became essential, due to the reported decrease in the immunity among the vaccinated population [30,31]; hence, the topic of current research became more crucial to be assessed. To the best of our knowledge, this study is a pioneer study evaluating the hesitancy against COVID-19 vaccine BD among healthcare professionals in Pakistan. The current study has shown that more than half of the study participants (52.1%) reported acceptance of a BD of the COVID-19 vaccine, while 34.7% rejected taking the BD. Among the study participants, 24.2% reported hesitancy to take a BD of the COVID-19 vaccine. A study among HCPs of Czech reported a higher level of COVID-19 vaccine BD acceptance (71.3%) [20], while the US HCPs have shown even more acceptance (92.1%) to take BDs COVID-19 vaccine [23]. The reported acceptance of BDs among the public of the Pakistani population ranged from 77.8% to 89.4% [32,33]. The participants of the current study that were infected by COVID-19, even after getting primer vaccine doses, could be the reason for the low acceptance of the BDs of the vaccine.
Approximately one-fourth of the study participants (23.4%) reported being infected by COVID-19 previously, and the majority of the participants (55.9%) were infected with COVID-19 before the 1st dose of vaccine, which is consistent with other studies from Pakistan [32,33]. Most of the participants (95.7%) were vaccinated against COVID-19, and the furthest commonly administered vaccine type was the inactivated virus vaccine (66.2%), while a similar rate of vaccination (97%) was reported among the general population of Pakistan [32]. The vaccine rejection and hesitancy were more commonly seen among the participants who had taken the adenovirus vector vaccine previously, as compared to mRNA and inactivated virus vaccines, which is consistent with previous studies [20,24]. That could be due to the low efficacy and more intense side effects of the adenovirus vaccines, in comparison to mRNA vaccines and inactivated virus vaccines [34].

Almost half of the participants (47.8% to 54.6%) agreed about the perceived effectiveness, safety, and risk/benefit ratio of the COVID-19 vaccine’s BD, while a similar percentage of the participants (52.1%) accepted the BD of the COVID-19 vaccine. A prior study in Czech also revealed a similar ratio between BD acceptance and the psychological drivers of COVID-19 vaccine’s BD among the HCPs [20]. All the psychological drivers were significantly associated (p < 0.001) with the attitude of the participants towards vaccine BD (acceptance, rejection, or hesitancy), which was consistent with the results of a survey from Czechian HCPs [17]. It can be concluded from the similarity in the results of these studies from the different geographical regions that promoting the agreement on psychological drivers could reduce the hesitancy regarding the COVID-19 vaccine. Most of the participants reported the mRNA vaccine to be promoted for the booster dose, compared to our previous study, that was conducted at the time of the COVID-19 vaccine’s approval in Pakistan, which could be related to the circulation of conspiracy beliefs regarding the COVID-19 vaccine at that time [11].

There are some limitations in the current study. The study participants may not be the true representative of all Pakistani HCPs, as a snowball sampling technique was utilized, due to which, the results cannot be generalized. The SAQ was in the English language and circulated through the internet, so HCPs with limited English proficiency and limited internet availability may not have been able to participate in the study. The majority of participants were from the province of Punjab, which may have influenced the extrapolation of the results. The possible predictors, such as severe COVID-19 experiences of relatives, which were not included in the current study, may be considered a limitation of the study.

5. Conclusions

Under the umbrella of study limitations, only half of the Pakistani HCPs (52.1%) accepted the BD of the COVID-19 vaccine, whereas 24.2% were still hesitant, and 34.7% were against the administration of BDs. The perceived effectiveness (against severe illness and symptomatic infection), perceived safety (equally safe as primer dose, the occurrence of side effects), perceived risk–benefit ratio, self-prioritization, satisfaction with the previously administered vaccine, and selectivity of BD were found to be robust predictors for the acceptance of the BD, while effectiveness against community transmission and mutation control were not important for the targeted population. The policymakers and the health administration should take the necessary steps to enhance the agreement of HCPs with psychological drivers of COVID-19 vaccine BD through evidence-based educational approaches, such as seminars, educational videos, and by supplying of latest clinical literature, regarding vaccines, for the reduction of VBH.

Author Contributions: Conceptualization, M.S.A. and M.F.R.; methodology, M.S.A., I.M., M.O.C. and M.F.R.; software, H.S., I.A., M.A. and M.F.R.; validation, I.M. and I.I. (Imran Imran); formal analysis, M.S.A., I.I. (Iqra Ishaq), H.Y., M.O.C. and M.F.R.; investigation, I.M., H.S., M.A. and M.F.R.; data curation, M.S.A., I.A., I.I. (Iqra Ishaq), H.Y. and M.F.R.; writing—original draft preparation, M.S.A., I.I. (Iqra Ishaq), H.Y., M.A. and I.A.; writing—review and editing, I.M., H.S., I.I. (Imran Imran), M.O.C. and M.F.R.; supervision, M.F.R.; project administration, M.F.R., H.S. and I.I. (Imran Imran). All authors have read and agreed to the published version of the manuscript.
**Funding:** This research received no external funding.

**Institutional Review Board Statement:** The current study was approved by the ethics committee of the Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan (reference No. Acad/PRAC/22/03).

**Informed Consent Statement:** Electronic consent was obtained from the participants, with an introductory section of the survey detailing the purpose, nature of the survey, volunteer participation, and declaration of confidentiality.

**Data Availability Statement:** The data that support the findings of this study are available from the corresponding author upon reasonable request.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Gebru, A.A.; Birhanu, T.; Wendimu, E.; Ayalew, A.F.; Mulat, S.; Abasimel, H.Z.; Kazemi, A.; Tadesse, B.A.; Gebru, B.A.; Deriba, B.S. Global burden of COVID-19: Situational analysis and review. *Hum. Antibodies* 2021, 29, 139–148. [CrossRef]

2. World Health Organization (WHO). Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int/ (accessed on 24 April 2022).

3. Yan, Z.-P.; Yang, M.; Lai, C.-L. COVID-19 vaccines: A review of the safety and efficacy of current clinical trials. *Pharmaceuticals* 2021, 14, 406. [CrossRef] [PubMed]

4. Fan, Y.-J.; Chan, K.-H.; Hung, I.F.-N. Safety and Efficacy of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Different Vaccines at Phase 3. *Vaccines* 2021, 9, 989. [CrossRef] [PubMed]

5. Dagan, N.; Barda, N.; Kepten, E.; Miron, O.; Perchik, S.; Katz, M.A.; Hernán, M.A.; Lipsitch, M.; Reis, B.; Balicer, R.D. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. *N. Engl. J. Med.* 2021, 384, 1412–1423. [CrossRef]

6. Shekhar, R.; Garg, I.; Pal, S.; Kottewar, S.; Sheikh, A.B. COVID-19 Vaccine Booster: To Boost or Not to Boost. *Infect. Dis. Rep.* 2021, 13, 924–929. [CrossRef] [PubMed]

7. Arbel, R.; Hammerman, A.; Sergienko, R.; Friger, M.; Peretz, A.; Netzer, D.; Yaron, S. BNT162b2 vaccine booster and mortality due to Covid-19. *N. Engl. J. Med.* 2021, 385, 2413–2420. [CrossRef] [PubMed]

8. Andrews, N.; Stowe, J.; Kirsebom, F.; Toffa, S.; Rickeard, T.; Gallagher, E.; Gower, C.; Kall, M.; Groves, N.; O’Connell, A.-M. High rates of COVID-19 vaccine hesitancy and its association with conspiracy beliefs: A study in Jordan and Kuwait among other Arab countries. *Vaccines* 2021, 9, 42. [CrossRef] [PubMed]

9. Qayyum, I. Top ten global health threats for 2019: The WHO list. *J. Rehman Med. Inst.* 2019, 5, 1–2.

10. MacDonald, N.E. Vaccine hesitancy: Definition, scope and determinants. *Vaccine* 2015, 33, 4161–4164. [CrossRef]

11. Arshad, M.S.; Hussain, I.; Mahmood, T.; Hayat, K.; Majeed, A.; Imran, I.; Saeed, H.; Iqbal, M.O.; Uzair, M.; Rehman, A.U. A National Survey to Assess the COVID-19 Vaccine-Related Conspiracy Beliefs, Acceptability, Preference, and willingness to pay among the general population of Pakistan. *Vaccines* 2021, 9, 720. [CrossRef]

12. Sallam, M.; Dababsheh, D.; Eid, H.; Al-Mahzoum, K.; Al-Haidar, A.; Taim, D.; Yaseen, A.; Ababneh, N.A.; Bakri, F.G.; Mahafzah, A. High rates of COVID-19 vaccine hesitancy and its association with conspiracy beliefs: A study in Jordan and Kuwait among other Arab countries. *Vaccines* 2021, 9, 42. [CrossRef] [PubMed]

13. Joshi, A.; Kaur, M.; Kaur, R.; Grover, A.; Nash, D.; El-Mohandes, A. Predictors of COVID-19 vaccine acceptance, intention, and hesitancy: A scoping review. *Front. Public Health* 2021, 9, 698111. [CrossRef]

14. Sallam, M. COVID-19 vaccine hesitancy worldwide: A concise systematic review of vaccine acceptance rates. *Vaccines* 2021, 9, 160. [CrossRef]

15. Tahir, M.J.; Saqlain, M.; Tariq, W.; Waheed, S.; Tan, S.H.; Nasir, S.I.; Ullah, I.; Ahmed, A. Population preferences and attitudes towards COVID-19 vaccination: A cross-sectional study from Pakistan. *BMC Public Health* 2021, 21, 1759. [CrossRef] [PubMed]

16. Chaudhary, F.A.; Ahmad, B.; Khalid, M.D.; Fazal, A.; Javaid, M.M.; Butt, D.Q. Factors influencing COVID-19 vaccine hesitancy and acceptance among the Pakistani population. *Hum. Vaccin. Immunother.* 2021, 17, 3365–3370. [CrossRef] [PubMed]

17. Yasmin, F.; Asghar, W.; Babar, M.S.; Khan, H.; Ahmad, S.; Hameed, Z.; Asghar, M.S.; Nauman, H.; Khattak, A.K.; Arshad, Z. Acceptance rates and beliefs toward COVID-19 vaccination among the general population of Pakistan: A cross-sectional survey. *Am. J. Trop. Med. Hyg.* 2021, 105, 1230. [CrossRef]

18. Dooling, K.; McClung, N.; Chamberland, M.; Marin, M.; Wallace, M.; Bell, B.P.; Lee, G.M.; Talbot, H.K.; Romero, J.R.; Oliver, S.E. The advisory committee on immunization practices’ interim recommendation for allocating initial supplies of COVID-19 vaccine—United States, 2020. *Morb. Mortal. Weekly Rep.* 2020, 69, 1857. [CrossRef]

19. Katzman, J.G.; Katzman, J.W. Primary care clinicians as COVID-19 vaccine ambassadors. *J. Prim. Care Community Health* 2021, 12, 2150132721100702. [CrossRef]

20. Klugar, M.; Riad, A.; Mobaner, L.; Pokorná, A. COVID-19 vaccine booster hesitancy (VBH) of healthcare workers in Czechia: National cross-sectional study. *Vaccines* 2021, 9, 1437. [CrossRef]

21. Koh, S.W.C.; Tan, H.M.; Lee, W.H.; Mathews, J.; Young, D. COVID-19 vaccine booster hesitancy among healthcare workers: A retrospective observational study in Singapore. *Vaccines* 2022, 10, 464. [CrossRef]
22. Yadete, T.; Batra, K.; Netski, D.M.; Antonio, S.; Patros, M.J.; Bester, J.C. Assessing acceptability of COVID-19 vaccine booster dose among adult Americans: A cross-sectional study. Vaccines 2021, 9, 1424. [CrossRef]
23. Pal, S.; Shekhar, R.; Kottewar, S.; Upadhyay, S.; Singh, M.; Pathak, D.; Kapuria, D.; Barrett, E.; Sheikh, A.B. COVID-19 vaccine hesitancy and attitude toward booster doses among US healthcare workers. Vaccines 2021, 9, 1358. [CrossRef]
24. Lounis, M.; Bencherit, D.; Rais, M.A.; Riad, A. COVID-19 Vaccine Booster Hesitancy (VBH) and Its Drivers in Algeria: National Cross-Sectional Survey-Based Study. Vaccines 2022, 10, 621. [CrossRef] [PubMed]
25. Yoshida, M.; Kobashi, Y.; Kawamura, T.; Shimazu, Y.; Nishikawa, Y.; Omata, F.; Zhao, T.; Yamamoto, C.; Kaneko, Y.; Nakayama, A. Factors Associated with COVID-19 Vaccine Booster Hesitancy: A Retrospective Cohort Study, Fukushima Vaccination Community Survey. Vaccines 2022, 10, 515. [CrossRef] [PubMed]
26. Government of Pakistan. COVID-19 Health Advisory Platform by Ministry of National Health Services Regulation and Coordination, Vaccine Statistics. Available online: https://covid.gov.pk/ (accessed on 24 April 2022).
27. Vandenbroucke, J.P.; Elm, E.v.; Altman, D.G.; Gøtzsche, P.C.; Mulrow, C.D.; Pocock, S.J.; Poole, C.; Schlesselman, J.J.; Egger, M.; Initiative, S. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration. Ann. Intern. Med. 2007, 147, W-63–W-194. [CrossRef]
28. Pakistan Bureau of Statistics, Social Indicators of Pakistan 2021. Available online: https://www.pbs.gov.pk/sites/default/files/social_statistics/publications/Social_Indicators_of_Pakistan_2021.pdf (accessed on 30 September 2022).
29. Eysenbach, G. Improving the quality of Web surveys: The Checklist for Reporting Results of Internet E-Surveys (CHERRIES). J. Med. Internet Res. 2004, 6, e132. [CrossRef] [PubMed]
30. Ward, H.; Whitaker, M.; Flower, B.; Tang, S.N.; Atchison, C.; Darzi, A.; Donnelly, C.A.; Cann, A.; Diggle, P.J.; Ashby, D. Population antibody responses following COVID-19 vaccination in 212,102 individuals. Nat. Commun. 2022, 13, 1–6. [CrossRef]
31. Uysal, E.B.; Gümü¸s, S.; Bektöre, B.; Bozkurt, H.; Gözalan, A. Evaluation of antibody response after COVID-19 vaccination of healthcare workers. J. Med. Virol. 2022, 94, 1060–1066. [CrossRef]
32. Amjad, F.; Parvi, M.Z.; Shamsi, U.; Hannan, E.; Jamil, Z.; Nabi, H.; Qureshi, I.A.; Sadiq, M.W.; Shaikh, F. Acceptance of COVID-19 Booster in the Adult Population of Pakistan: A Cross Sectional Study. 2022. Available online: https://assets.researchsquare.com/files/rs-1792835/v1/580d616e-4891-4341-94c5-4076b4df03a.pdf?c=1657687451 (accessed on 31 August 2022).
33. Seboka, B.T.; Moeed, A.; Najeeb, H.; Saleem, A.; Asghar, M.S.; Rafi, H.M.; Khattak, A.K.; Bilal, Z. Willingness and Perceptions Regarding COVID-19 Vaccine Booster Dose in Pakistani Vaccinated Population: A Cross-Sectional Survey. Front. Public Health 2022, 10, 911518. [CrossRef]
34. Pormohammad, A.; Zarei, M.; Ghorbani, S.; Mohammad, M.; Razizadeh, M.H.; Turner, D.L.; Turner, R.J. Efficacy and safety of COVID-19 vaccines: A systematic review and meta-analysis of randomized clinical trials. Vaccines 2021, 9, 467. [CrossRef] [PubMed]